Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis

• DOI: 10.1007/bf02236902
• Publication Date: 2005-10-21T03:13:01Z
• Authors: P. Gionchetti; F. Rizzello; A. Venturi; M. Ferretti; C. Brignola; M. Miglioli; M. Campieri
• Keywords: Mesalazine; Suppository; Demographics

The aim of our study was to compare the efficacy and safety oral mesalazine with suppositories in patients active ulcerative proctitis.A four-week, randomized, single-blind trial performed 58 active, histologically confirmed proctitis (< or = 15 cm) evaluate 800-mg tablets taken three times per day (n 29) compared 400 mg administered 29). Patients were evaluated at entry after two four weeks. Efficacy evaluations included a disease activity index, which represents score variables: stools frequency, rectal bleeding, mucosal appearance, physician's assessment severity. Histologic also assessed weeks accordance criteria by Truelove Richard. Safety clinical laboratory parameters adverse event reports.There no significant differences regard baseline comparisons demographics severity between treatment groups. Improvement mean index significantly greater mesalazine, both two-week four-week visits (mean scores baseline, two, weeks: 7.7, 2.59, 1.48; 7.42, 5.72, 3.48, respectively (P < 0.001)). rate histologic remission 0.01). There events results groups.Results this indicate that produces earlier better than proctitis.